300942 Shenzhen Bioeasy Biotechnology
- 6.45
- -0.12-1.83%
Shenzhen Bioeasy Biotechnology News
Yirui Bioscience (300942.SZ): has successfully opened blank markets in France, Germany, Switzerland, Portugal, Morocco, etc.
Gelonghui, September 14th | Yirui Biology (300942.SZ) stated at the investor relations event that in the first half of 2024, the company has successfully opened up blank markets in France, Germany, Swiss franc, Portugal, Morocco, and achieved widespread recognition and good feedback for dairy product testing products in markets such as Turkey and Brazil. At the same time, the company further develops potential customer groups, improves customer stickiness and satisfaction by accelerating the expansion of international government projects for pesticide residue rapid detection products, and providing customized solutions for testing requirements in different countries and regions.
Yirui Biotech: Summary of the 2024 Semi-Annual Report
Yirui Biotech: 2024 Semi-Annual Report
Yirui Bio (300942.SZ) released its performance for the first half of the year, with a net loss of 1.5595 million yuan.
Yirui Biotechnology (300942.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
In the first half of the year, Yirui Biological (300942.SZ) reported a net loss of 1.5595 million yuan.
On August 29, 8ainlin announcemented the interim report for the first half of 2024, with operating revenue of 0.104 billion yuan, a year-on-year decrease of 7.55%; net profit attributable to shareholders of listed companies -1.5595 million yuan, a narrower year-on-year loss; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was -5.2591 million yuan; and basic earnings per share was -0.0039 yuan.
What Shenzhen Bioeasy Biotechnology Co., Ltd.'s (SZSE:300942) P/S Is Not Telling You
Yirui Biotechnology (300942.SZ): The company's in vitro diagnostic business has greatly shrunk. Currently, the company is focusing on steady development of the food safety rapid detection business.
Yirui Biology (300942.SZ) stated on its investor platform on July 16th that its in vitro diagnostic business has greatly shrunk, and the company is currently focusing on the steady development of its food safety rapid detection business. The main reason for the loss in the first quarter was the shrinkage of the in vitro diagnostic business and the influence of seasonal factors on the income of the food safety business, but the corresponding fixed costs such as rent and personnel wages remained at a certain level.
Yirui Biological (300942.SZ): The concerted action person of the actual controller plans to reduce the shareholding by a total of no more than 735,800 shares.
On June 13th, Gelunhui reported that Yirui Biology (300942.SZ) announced that the company's controlling shareholder and actual controller's consistent action person, Shenzhen Yida Rui Management Consulting Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Yida Rui') and Shenzhen Yikai Rui Management Consulting Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Yikai Rui') plan to reduce their holdings of company shares through centralized bidding or bulk trading within three months (from July 5th, 2024 to October 4th, 2024) after 15 trading days from the date of announcement disclosure. The specific details are as follows: 1. Holds 19,762,903 shares of the company (accounting for
Private Companies Are Shenzhen Bioeasy Biotechnology Co., Ltd.'s (SZSE:300942) Biggest Owners and Were Hit After Market Cap Dropped CN¥397m
Yi Rui Biotech (300942.SZ): Financial director changed to Wang Guangsheng
Gelonghui, May 24, 丨 Yi Rui Biotech (300942.SZ) announced that the company's board of directors recently received the resignation report from Mr. Wan Kai, the company's financial director. Mr. Wan Kai applied to resign as the company's financial director due to personal reasons. The original term was from April 1, 2024 to March 31, 2027. After his resignation, he no longer held any position in the company. Nominated by the company's general manager, approved by the board nomination committee's qualification review, and reviewed and approved by the board audit committee, the board of directors agreed to appoint Mr. Wang Guangsheng as the company's financial director. The term of office begins on the date of review and approval by the board of directors until the end of the third board of directors of the company
The controlling shareholder, actual controller and co-actors of Yirui Biotech (300942.SZ) intend to transfer 6.59% of the shares by agreement
Yi Rui Biotech (300942.SZ) announced that the controlling shareholder of the company, Yi Rui (Hainan) Venture Capital Co., Ltd. (“Easy...
Yirui Biotech (300942.SZ): Net loss of 7.11,111 million yuan in the first quarter
On April 25, Ge Longhui Biotech (300942.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 364.751 million yuan, a year-on-year decrease of 39.92%; net profit attributable to shareholders of listed companies - 7.1111 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 8.418,500 yuan; basic earnings per share - 0.02 yuan.
Yirui Biotech (300942.SZ) controlling shareholder, Yirui Venture Capital, actual controller Zhu Hai, and majority shareholder Yidarui plan to transfer 6.59% of the shares in total
Yi Rui Biotech (300942.SZ) announced that the company received the controlling shareholder, Zhu Hai, the actual controller, and shares...
The controlling shareholder of Yirui Biotech (300942.SZ) pledges 80 million shares
Yi Rui Biotech (300942.SZ) announced that the company recently received venture capital from the company's controlling shareholder, Yi Rui (Hainan)...
Yirui Biology (300942.SZ): The main products in the rapid food safety testing business are rapid food safety detection reagents, rapid testing instruments and related rapid inspection services
On March 19, Gelonghui Biotech (300942.SZ) said on the investor interactive platform that the main products of the company's rapid food safety testing business are rapid food safety testing reagents, rapid testing instruments and related rapid inspection services. Currently, the company has a research and development plan for products related to household food safety testing. It is simple, fast, and efficient, and can meet the needs of home testing for veterinary drug residues, pesticide residues, and mycotoxins in food. In the future, the company will continue to develop new products and continue to seek more market opportunities and development space.
Revenues Not Telling The Story For Shenzhen Bioeasy Biotechnology Co., Ltd. (SZSE:300942) After Shares Rise 27%
Yirui Biotech (300942.SZ): The ban on 273 million shares issued before the initial launch will be lifted on February 20
Gelonghui, Feb. 8, 丨 Yi Rui Biotech (300942.SZ) announced an indicative announcement on the listing and circulation of shares issued prior to the initial public offering. The restricted shares listed in circulation are shares issued by the company before the initial public offering. The number of shares that have been lifted this time is 273 million shares, accounting for 68.18% of the company's total share capital. The sales restriction period is 36 months from the date of stock listing. The listing and circulation date for the shares whose sales restrictions have been lifted is February 20, 2024 (Tuesday).
Shenzhen Bioeasy Biotechnology Co., Ltd. (SZSE:300942) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Is Shenzhen Bioeasy Biotechnology (SZSE:300942) Using Debt In A Risky Way?
Yirui Biotech (300942.SZ): Currently, there are no seafood nuclear pollution testing products
On December 25, Gelonghui Biotech (300942.SZ) stated on the investor interactive platform that some of our products can quickly test veterinary drug residues, food additives, etc. common in aquatic products. Currently, there are no seafood nuclear pollution testing products. The company will pay close attention to the specific development of this incident, rely on the company's technical advantages and R&D reserves, and formulate R&D plans according to the development of the situation and make timely adjustments.
Analysis
Price Target
No Data
No Data